Genital Wart: Clinical Trials

10 trials for Genital Wart, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 unknown, 3 completed, 1 active not recruiting, 1 recruiting. 10 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 310Unknown 4, Completed 3, Active not recruiting 1, Recruiting 1, Terminated 1

Follow Genital Wart: new trials by email Literature Review of Genital Wart trials Research Report on Genital Wart

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha), Placebo - Genital Wart, Penile Cancer
Phase 3Active not recruitingShanghai Bovax Biotechnology Co., Ltd.90002024-07-112024-12-12
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha), Placebo - Cervical Cancer, Genital Wart
Phase 3TerminatedShanghai Bovax Biotechnology Co., Ltd.31312022-12-092023-07-21
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
Zerun HPV-9, GARDASIL ®9 - Cervical Cancer, Genital Wart
Phase 3UnknownShanghai Zerun Biotechnology Co.,Ltd12002022-09-012022-10-28
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years - HPV Infections, Cervical Cancer Stage IIa
Phase 3UnknownShanghai Bovax Biotechnology Co., Ltd.13482021-09-152024-04-17
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
9-valent HPV vaccine - HPV Infections, Cervical Cancer
Phase 3UnknownShanghai Bovax Biotechnology Co., Ltd.12002021-05-282024-04-17
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9 - HPV Infections, Cervical Cancer
Phase 3CompletedShanghai Bovax Biotechnology Co., Ltd.12002020-09-192023-11-24
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL® - Cervical Cancer, Vulvar Cancer
Phase 3CompletedShanghai Bovax Biotechnology Co., Ltd.16802020-05-282022-02-25
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL® - Cervical Cancer, Vulvar Cancer
Phase 3RecruitingShanghai Bovax Biotechnology Co., Ltd.80002020-04-282024-06-07
Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients
tuberculin, cryotherapy - Genital Wart
Phase 3UnknownAssiut University452017-06-012017-05-17
Low Dose Cyclophosphamide Treats Genital Warts
cyclophosphamide - Genital Wart
Phase 3CompletedHuazhong University of Science and Technology1042007-01-012009-11-25

Narrower conditions

Condylomata Acuminata (10)  ·  Uterine Cervical Neoplasms (7)  ·  Vaginal Neoplasms (5)  ·  Papillomavirus Infections (4)  ·  Vulvar Neoplasms (4)  ·  Anus Neoplasms (1)  ·  Penile Neoplasms (1)

Broader conditions

Communicable Diseases (10)  ·  DNA Virus Infections (10)  ·  Disease Attributes (10)  ·  Genital Diseases (10)  ·  Infections (10)  ·  Pathologic Processes (10)  ·  Pathological Conditions, Signs and Symptoms (10)  ·  Sexually Transmitted Diseases (10)  ·  Sexually Transmitted Diseases, Viral (10)  ·  Skin Diseases (10)  ·  Skin Diseases, Infectious (10)  ·  Skin Diseases, Viral (10)  ·  Skin and Connective Tissue Diseases (10)  ·  Tumor Virus Infections (10)  ·  Urogenital Diseases (10)

Interventions

Vaccines, Synthetic (3)  ·  Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (2)  ·  Cryotherapy (1)  ·  Cyclophosphamide (1)  ·  Tuberculin (1)

Sponsors

Shanghai Bovax Biotechnology Co., Ltd. (7)  ·  Assiut University (1)  ·  Huazhong University of Science and Technology (1)  ·  Shanghai Zerun Biotechnology Co.,Ltd (1)

Countries

China (9)

Top investigators

Bo Huang, PH.D, MD (1)  ·  Lidong Gao, Master (1)  ·  Long Sui, Doctor (1)  ·  Ting Huang (1)

Results publications

PMID 11238198, PMID 12807939, PMID 15897380, PMID 16973081, PMID 23336207, PMID 25273231